Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 275.10 Mil Enterprise Value: 126.27 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 50/100

Q2 2024 Lexicon Pharmaceuticals Inc Earnings Call Transcript

Aug 01, 2024 / 09:00PM GMT
Release Date Price: €4.1
Operator

Good day and welcome to the Lexicon Pharmaceuticals second-quarter 2024 financial results conference call. (Operator instructions) Please note this event is being recorded.

I would now like to turn the conference over to Lisa de Francesco, Head Investor Relations and Corporate Strategy. Please go ahead.

Lisa DeFrancesco
Lexicon Pharmaceuticals Inc - Head- Investor Relations and Corporate Developmen

Thank you, Betsy. Good afternoon, and welcome to the Lexicon Pharmaceuticals second-quarter 2024 financial results conference call. Joining me today are Dr. Mike Exton, Lexicon's new Chief Executive Officer and Director; Jeff Wade, President and Chief Operating Officer; Tom Garner, Senior Vice President and Chief Commercial Officer; Dr. Craig Granowitz, Senior Vice President and Chief Medical Officer; and Dr. Alan Main, Executive Vice President, Innovation and Chemical Sciences.

Earlier this afternoon, Lexicon issued a press release announcing our financial results for the second quarter of 2024, which is available on our website at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot